This page uses content from Wikipedia and is licensed under CC BY-SA.

Allosteric modulator

In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimulus. Some of them, like benzodiazepines, are drugs.[1] The site that an allosteric modulator binds to (i.e., an allosteric site) is not the same one to which an endogenous agonist of the receptor would bind (i.e., an orthosteric site). Modulators and agonists can both be called receptor ligands.[2]

Modulators are either positive, negative or neutral. Positive types increase the response of the receptor by either increasing the probability that an agonist will bind to a receptor (i.e. affinity), or increasing its ability to activate the receptor (i.e. efficacy), or both. Negative types decrease the agonist affinity and/or efficacy. Neutral types don't affect agonist activity, but can stop other modulators from binding to an allosteric site. Some modulators also work as allosteric agonists.

The term "allosteric" derives from the Greek language. Allos means "other", and stereos, "solid" or "shape". This can be translated to "other shape", which indicates the conformational changes within receptors caused by the modulators through which the modulators affect the receptor function.[3]


Allosteric modulators can alter the affinity and efficacy of other substances acting on a receptor. A modulator may also increase affinity and lower efficacy or vice versa.[4] Affinity is the ability of a substance to bind to a receptor. Efficacy is the ability of a substance to activate a receptor, given as a percentage of the ability of the substance to activate the receptor as compared to the receptor's endogenous agonist. If efficacy is zero, the substance is considered an antagonist.[1]

Orthosteric agonist (A) binds to orthosteric site (B) of a receptor (E). Allosteric modulator (C) binds to allosteric site (D). Modulator increases/lowers the affinity (1) and/or efficacy (2) of an agonist. Modulator may also act as an agonist and yield an agonistic effect (3). Modulated orthosteric agonist affects the receptor (4). Receptor response (F) follows.

The site to which endogenous agonists bind to is named the orthosteric site. Modulators don't bind to this site. They bind to any other suitable sites, which are named allosteric sites.[2] Upon binding, modulators generally change the three-dimensional structure (i.e. conformation) of the receptor. This will often cause the orthosteric site to also change, which can alter the effect of an agonist binding.[4] Allosteric modulators can also stabilize one of the normal configurations of a receptor. [5]

In practice, modulation can be complicated. A modulator may function as a partial agonist, meaning it doesn't need the agonist it modulates to yield agonistic effects.[6] Also, modulation may not affect the affinities or efficacies of different agonists equally. If a group of different agonists that should have the same action bind to the same receptor, the agonists might not be modulated the same by some modulators.[4]


A modulator can have 3 effects within a receptor. One is its capability or incapability to activate a receptor (2 possibilities). The other two are agonist affinity and efficacy. They may be increased, lowered or left unaffected (3 and 3 possibilities). This yields 17 possible modulator combinations.[4] There are 18 (=2*3*3) if neutral modulator type is also counted.

For all practical considerations, these combinations can be generalized only to 5 classes[4] and 1 neutral:

  • positive allosteric modulators (PAM) increase agonist affinity and/or efficacy.[4] Clinical examples are benzodiazepines like diazepam, alprazolam and chlordiazepoxide, which modulate GABAA-receptors, and cinacalcet, which modulates calcium-sensing receptors.[7]
    • PAM-agonists work like PAMs, but also as agonists with and without the agonists they modulate.[4]
    • PAM-antagonists work like PAMs, but also function as antagonists and lower the efficacy of the agonists they modulate.[4]
  • negative allosteric modulators (NAM) lower agonist affinity and/or efficacy.[4] Maraviroc is a medicine that modulates CCR5. Fenobam, raseglurant and dipraglurant are experimental GRM5 modulators.[7]
    • NAM-agonists work like NAMs, but also as agonists with and without the agonists they modulate.[4]
  • neutral allosteric modulators don't affect agonist activity, but bind to a receptor and prevent PAMs and other modulators from binding to the same receptor thus inhibiting their modulation.[4] Neutral modulators are also called silent allosteric modulators (SAM)[6] or neutral allosteric ligands (NAL). An example is 5-methyl-6-(phenylethynyl)-pyridine (5MPEP), a research chemical, which binds to GRM5.[8]


CX614, a PAM for an AMPA receptor binding to an allosteric site and stabilizing the closed conformation

Due the variety of locations on receptors that can serve as sites for allosteric modulation, as well as the lack of regulatory sites surrounding them, allosteric modulators can act in a wide variety of mechanisms.

Modulating Binding

Many allosteric modulators induce a conformational change in their target receptor which increases the binding affinity of the agonist. This causes the receptors to activate more frequently, but does not affect how long an associated channel is open or the current through the channel. Benzodiazapines act via this mechanism, by binding between the α and γ subunits of GABA receptors and increasing GABA binding. [9]

Modulating Unbinding

Some modulators act to stabilize conformational changes associated with the agonist-bound state. This increases the probability that the receptor will be in the activated conformation, although it does not prevent the receptor from switching back to the deactivated state. With a higher probability of remaining in the activated state, the receptor will bind agonist for longer durations. AMPA receptors modulated by CX614 (pyrrolidino-1,3-oxazino benzo-1,4-dioxan-10-one) will deactivate slower, and facilitate more overall cation transport. This is likely accomplished by CX614 binding to the back of the "clam shell" that contains the binding site for glutamate, stabilizing the closed conformation associated with activation of the AMPA receptor. [10]

Preventing Desensitization

Overall signal can be increased by preventing the desensitization of a receptor. Desensitization prevents a receptor from activating, despite the presence of agonist. This is often caused by repeated or intense exposures to agonist. Eliminating or reducing this phenomenon increasing the receptor's overall activation. AMPA receptors are susceptible to desensitization via a disruption of a ligand binding domain dimer interface. Cyclothiazide has been shown to stabilize this interface and slow desensitization, and is therefore considered a positive allosteric modulator. [9][11]

Stabilizing Active/Inactive Conformation

Modulators can directly regulate receptors rather than affecting the binding of the agonist. Similar to stabilizing the bound conformation of the receptor, a modulator that acts in this mechanism stabilizes a conformation associated with the active or inactive state. This increases the probability that the receptor will conform to the stabilized state, and modulate the receptor's activity accordingly. Calcium-Sensing Receptors (CaSR) can be modulated in this way by adjusting the pH. Lower pH increases the stability of the inactive state, and thereby decreases the sensitivity of the receptor. It is speculated that the changes in charges associated with adjustments to pH cause a conformational change in the receptor favoring inactivation. [9]

Interaction with agonists

Modulators that increase only the affinity of partial and full agonists allow their efficacy maximum to be reached sooner at lower agonist concentrations – i.e. the slope and plateau of a dose-response curve shift to lower concentrations.[4]

Efficacy increasing modulators increase maximum efficacy of partial agonists. Full agonists already activate receptors fully so modulators don't affect their maximum efficacy, but somewhat shift their response curves to lower agonist concentrations.[4]

Medical importance


Related receptors have orthosteric sites that are very similar in structure, as mutations within this site may especially lower receptor function. This can be harmful to organisms, so evolution doesn't often favor such changes. Allosteric sites are less important for receptor function, which is why they often have great variation between related receptors. This is why, in comparison to orthosteric drugs, allosteric drugs can be very specific, i.e. target their effects only on a very limited set of receptor types. However, such allosteric site variability occurs also between species so the effects of allosteric drugs vary greatly between species.[12]

Modulators can't turn receptors fully on or off as modulator action depends on endogenous ligands like neurotransmitters, which have limited and controlled production within body. This can lower overdose risk relative to similarly acting orthosteric drugs. It may also allow a strategy where doses large enough to saturate receptors can be taken safely to prolong the drug effects.[4] This also allows receptors to activate at prescribed times (i.e. in response to a stimulus) instead of being activated constantly by an agonist, irrespective of timing or purpose. [13]

Modulators affect the existing responses within tissues and can allow tissue specific drug targeting. This is unlike orthosteric drugs, which tend to produce a less targeted effect within body on all of the receptors they can bind to.[4]

Some modulators have also been shown to lack the desensitizing effect that some agonists have. Nicotinic acetylcholine receptors, for example, quickly desensitize in the presence of agonist drugs, but maintain normal function in the presence of PAMs. [14]


Allosteric modulation has demonstrated as beneficial to many conditions that have been previously difficult to control with other pharmaceuticals. These include:

  • Reducing the negative symptoms (defecits) associated with schizophrenia using 4-Nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide [15]
  • Reducing anxiety by positively regulating GABA receptors. [9]
  • Reducing the intensity of sleep disorders by positively regulating GABA receptors. [9]
  • Reducing symptoms of major depressive disorder by regulating dopamine receptors. [16]

See also


  1. ^ a b Rang HP, Ritter JM, Flower RJ, Henderson G (2016). Rang and Dale's pharmacology (8th ed.). Elsevier. pp. 6–20. ISBN 978-0-7020-5362-7.
  2. ^ a b Neubig RR, Spedding M, Kenakin T, Christopoulos A (December 2003). "International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology" (PDF). Pharmacological Reviews. 55 (4): 597–606. doi:10.1124/pr.55.4.4. PMID 14657418.
  3. ^ Nelson DL, Cox MM (2008). Lehninger Principles of Biochemistry (5th ed.). W.H. Freeman. pp. 162. ISBN 978-0-7167-7108-1.
  4. ^ a b c d e f g h i j k l m n o p q r s t Kenakin TP (2017). Pharmacology in drug discovery and development: understanding drug response (2nd ed.). Academic Press. pp. 102–119. doi:10.1016/B978-0-12-803752-2.00005-3. ISBN 978-0-12-803752-2.
  5. ^ Jin, Rongsheng; Clark, Suzanne; Weeks, Autumn M.; Dudman, Joshua T.; Gouaux, Eric; Partin, Kathryn M. (2005-09-28). "Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors". Journal of Neuroscience. 25 (39): 9027–9036. doi:10.1523/JNEUROSCI.2567-05.2005. ISSN 0270-6474. PMID 16192394.
  6. ^ a b Stephens B, Handel TM (2013). Chemokine receptor oligomerization and allostery. Progress in Molecular Biology and Translational Science. 115. Academic Press. pp. 4–5. doi:10.1016/B978-0-12-394587-7.00009-9. ISBN 978-0-12-394587-7. PMC 4072031. PMID 23415099.
  7. ^ a b Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al. (February 2012). "Allosteric modulation of 7 transmembrane spanning receptors: theory, practice, and opportunities for CNS drug discovery". Journal of Medicinal Chemistry. 55 (4): 1445–64. doi:10.1021/jm201139r. PMC 3349997. PMID 22148748.
  8. ^ Hellyer SD, Albold S, Wang T, Chen AN, May LT, Leach K, Gregory KJ (May 2018). "5 Allosteric Ligands". Molecular Pharmacology. 93 (5): 504–514. doi:10.1124/mol.117.111518. PMID 29514854.
  9. ^ a b c d e "Allosteric Modulator - an overview | ScienceDirect Topics". Retrieved 2019-12-13.
  10. ^ Jin, Rongsheng; Clark, Suzanne; Weeks, Autumn M.; Dudman, Joshua T.; Gouaux, Eric; Partin, Kathryn M. (2005-09-28). "Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors". Journal of Neuroscience. 25 (39): 9027–9036. doi:10.1523/JNEUROSCI.2567-05.2005. ISSN 0270-6474. PMID 16192394.
  11. ^ Jin, Rongsheng; Clark, Suzanne; Weeks, Autumn M.; Dudman, Joshua T.; Gouaux, Eric; Partin, Kathryn M. (2005-09-28). "Mechanism of Positive Allosteric Modulators Acting on AMPA Receptors". Journal of Neuroscience. 25 (39): 9027–9036. doi:10.1523/JNEUROSCI.2567-05.2005. ISSN 0270-6474. PMID 16192394.
  12. ^ Lu S, He X, Ni D, Zhang J (July 2019). "Allosteric Modulator Discovery: From Serendipity to Structure-Based Design". Journal of Medicinal Chemistry. 62 (14): 6405–6421. doi:10.1021/acs.jmedchem.8b01749. PMID 30817889.
  13. ^ Li, Yuanheng; Sun, Lilan; Yang, Taoyi; Jiao, Wenxuan; Tang, Jingshu; Huang, Xiaomin; Huang, Zongze; Meng, Ying; Luo, Laichun; Wang, Xintong; Bian, Xiling (01 10, 2019). "Design and Synthesis of Novel Positive Allosteric Modulators of α7 Nicotinic Acetylcholine Receptors with the Ability To Rescue Auditory Gating Deficit in Mice". Journal of Medicinal Chemistry. 62 (1): 159–173. doi:10.1021/acs.jmedchem.7b01492. ISSN 1520-4804. PMID 29587480. Check date values in: |date= (help)
  14. ^ Williams, Dustin K.; Wang, Jingyi; Papke, Roger L. (2011-10-15). "Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitations". Biochemical Pharmacology. Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science (Satellite to the 2011 Meeting of the Society for Neuroscience). 82 (8): 915–930. doi:10.1016/j.bcp.2011.05.001. ISSN 0006-2952.
  15. ^ Ayala, Jennifer E.; Chen, Yelin; Banko, Jessica L.; Sheffler, Douglas J.; Williams, Richard; Telk, Alexandra N.; Watson, Noreen L.; Xiang, Zixiu; Zhang, Yongqin; Jones, Paulianda J.; Lindsley, Craig W. (2009-08). "mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning". Neuropsychopharmacology. 34 (9): 2057–2071. doi:10.1038/npp.2009.30. ISSN 1740-634X. Check date values in: |date= (help)
  16. ^ Dremencov, Eliyahu; Weizmann, Yifat; Kinor, Noa; Gispan-Herman, Iris; Yadid, Gal (2006). "Modulation of Dopamine Transmission by 5HT2C and 5HT3 Receptors: A Role in the Antidepressant Response". Retrieved 2019-12-13.